...
首页> 外文期刊>Pakistan journal of medical sciences. >Predictive role of Glutathione S-transferases (GSTs) on the prognosis of osteosarcoma patients treated with chemotherapy
【24h】

Predictive role of Glutathione S-transferases (GSTs) on the prognosis of osteosarcoma patients treated with chemotherapy

机译:谷胱甘肽S-转移酶(GSTs)在骨肉瘤化疗患者预后中的预测作用

获取原文

摘要

Objective: We conducted a comprehensive study to investigate the role of GSTM1, GSTTI and GSTP1 genetic variation involved in transport pathways in response to chemotherapy and clinical outcome of osteosarcoma.Methods: A total of 146 patients were included in our study between January 2008 and December 2009. All the patients were followed up to death or January 2012. Genotyping of GSTM1, GSTT1 and GSTP1 was conducted in a 384-well plate format on the Sequenom MassARRAY platform.Results: Sixty seven patients (45.9%) died during the follow-up period. The median age of patients was 14.2 years and ranged from 9.3 to 38.7 years. The median follow-up time was 29.6 months (range 5 to 60 months). Individuals with GSTP1 G/G genotype tended to live shorter than A/A genotype, and we found a significantly higher risk of death from osteosarcoma (adjusted HR=2.73, 95% CI=1.05-7.45). Individuals with the GSTP GG genotype were more likely to have a poor response to chemotherapy, with an OR of 2.73 (95%CI, 1.07-7.81). However, we did not find association of polymorphisms in GSTM1 and GSTT1 with response to chemotherapy and prognosis of osteosarcoma.Conclusion: Our study provides information for prediction of treatment outcome in clinical oncology. Due to the limited number of samples, the results of our study need to be confirmed by large sample size studies.doi: http://dx.doi.org/10.12669/pjms.295.3870How to cite this:Teng JW, Yang ZM, Li J, Xu B. Predictive role of Glutathione S-transferases (GSTs) on the prognosis of osteosarcoma patients treated with chemotherapy. Pak J Med Sci 2013;29(5):1182-1186. doi: http://dx.doi.org/10.12669/pjms.295.3870This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
机译:目的:我们进行了一项全面的研究,以探讨GSTM1,GSTTI和GSTP1基因变异在运输途径中对化疗和骨肉瘤临床结局的影响。方法:2008年1月至12月间,本研究共纳入146例患者2009年。所有患者均获随访直至死亡或2012年1月。GSTM1,GSTT1和GSTP1基因分型在Sequenom MassARRAY平台上以384孔板进行。结果:67例患者(45.9%)在随后的随访中死亡上升期。患者的中位年龄为14.2岁,范围为9.3至38.7岁。中位随访时间为29.6个月(5到60个月不等)。 GSTP1 G / G基因型个体的寿命往往短于A / A基因型,并且我们发现骨肉瘤死亡的风险显着更高(校正后的HR = 2.73,95%CI = 1.05-7.45)。具有GSTP GG基因型的个体更有可能对化疗反应不良,OR为2.73(95%CI,1.07-7.81)。然而,我们并未发现GSTM1和GSTT1中的多态性与对化疗的反应和骨肉瘤的预后相关。结论:我们的研究为预测​​临床肿瘤学治疗结果提供了信息。由于样本数量有限,我们的研究结果需要通过大量样本研究来确认。doi:http://dx.doi.org/10.12669/pjms.295.3870如何引用此信息:Teng JW,Yang ZM ,Li J,Xu B.谷胱甘肽S-转移酶(GSTs)在化疗后骨肉瘤患者预后中的预测作用。 Pak J Med Sci 2013; 29(5):1182-1186。 doi:http://dx.doi.org/10.12669/pjms.295.3870这是根据知识共享署名许可(http://creativecommons.org/licenses/by/3.0)的条款分发的开放访问文章,只要适当引用了原始作品,便可以在任何介质中不受限制地使用,分发和复制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号